The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis

Schubert, Maria; Joniau, Steven; Gontero, Paolo; Kneitz, Susanne; Scholz, Claus-Jürgen; Kneitz, Burkhard; Briganti, Alberto; Karnes, R Jeffrey; Tombal, Bertrand; Walz, Jochen; Hsu, Chao-Yu; Marchioro, Giansilvio; Bader, Pia; Bangma, Chris; Frohneberg, Detlef; Graefen, Markus; Schröder, Fritz; van Cangh, Paul; van Poppel, Hein and Spahn, Martin (2012). The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. Advances in urology, 2012, p. 612707. Cairo (Egypt): Hindawi Publishing Corporation 10.1155/2012/612707

[img]
Preview
Text
612707.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n = 86) or no adjuvant ADT (group 2, n = 86). Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5-10-year clinical progression-free survival was 96.9% (94.3%) for group 1 and 73.7% (67.0%) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-risk and T3b margins positive disease at higher risk for progression. Conclusion. Patients with T2/T3a tumors are at low-risk for metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Spahn, Martin

ISSN:

1687-6369

Publisher:

Hindawi Publishing Corporation

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:38

Last Modified:

21 Dec 2014 07:28

Publisher DOI:

10.1155/2012/612707

PubMed ID:

22400018

Web of Science ID:

000266587100510

BORIS DOI:

10.7892/boris.15463

URI:

https://boris.unibe.ch/id/eprint/15463 (FactScience: 222810)

Actions (login required)

Edit item Edit item
Provide Feedback